BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Prochieve: Additional Phase III data

Additional data from the double-blind, international Phase III PREGNANT trial in 465 healthy pregnant women with a short cervical length showed that once-daily Prochieve 8% progesterone gel starting from 20-24 weeks gestation led to a preterm birth rate before 33 weeks gestation, the primary endpoint, of 8.9% vs. 16.1% for placebo vaginal gel (p=0.02). Prochieve also significantly reduced the rate of preterm birth before 28 (5.1% vs....

Read the full 313 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >